Anticoagulants are used to prevent new or recurrent venous or arterial thrombotic events and the majority of patients are treated for stroke prevention in atrial fibrillation. Until recently, warfarin was virtually the only oral anticoagulant used in North America and the most commonly used anticoagulant worldwide. Warfarin has been used in clinical practice for 60 years and there is an abundance of documentation about the drug, including many studies assessing its perioperative interruption. 1 Nevertheless, there is uncertainty about the optimal perioperative management, particularly regarding the need for intermediate use of a parenteral, short-acting anticoagulant. 2 A few ongoing large randomized trials are addressing this problem such as the BRIDGE and PERIOP 2 trials (ClinicalTrials.gov NCT00786474 and NCT00432796, respectively).
For the non-vitamin K antagonist oral anticoagulants (NOACs) even less is known about optimal perioperative management. 3, 4 For the oral thrombin inhibitor dabigatran a retrospective analysis of data derived from a phase III trial in patients with atrial fibrillation 5 demonstrated that the risk of bleeding complications was similar to that of the comparator, warfarin, both for elective and for emergency surgery or invasive procedures. 6 Recommendations on when to stop dabigatran before surgery were provided only halfway through the trial and there were no instructions regarding timing of resumption of dabigatran. There are currently no evidence-based practice guidelines for the perioperative management of dabigatran-treated patients. The lack of such guidelines is likely to lead to considerable variability in clinical practice, as has occurred with the perioperative management of warfarin-treated patients. 2 Thus, if perioperative management is too aggressive, for example, allowing too little time before surgery for dabigatran interruption 7 or premature resumption of dabigatran after surgery excessive perioperative bleeding may occur. On the other hand, allowing too much time between dabigatran interruption and resumption may expose patients to an increased risk for arterial thrombosis and venous thromboembolism.
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We therefore performed a prospective cohort study to evaluate the safety of a prespecified protocol for the timing of interruption and resumption of dabigatran for surgery or invasive procedures. The primary objective was to determine the risk of major bleeding complications. The time points were determined by the renal function and bleeding risk of the procedure for stopping and on actual bleeding and bleeding risk for resumption of dabigatran.
Methods

Study Design
This was a Canadian multicenter prospective cohort study. It was funded by the Heart and Stroke
Foundation of Canada. The manufacturer of dabigatran, Boehringer Ingelheim, had no involvement in the main study described here although the company funded a substudy on the laboratory assessment of the residual anticoagulation effect of dabigatran on the day of surgery.
The protocol was approved by the institutional review board of each participating center. All patients provided written informed consent.
The study was managed by the McMaster Transfusion Research Program. An independent event adjudication committee, whose members were not otherwise involved in the study, classified all suspected thromboembolic and bleeding events as well as the cause of any
deaths. An external data and safety monitoring board reviewed the safety outcomes periodically.
Study Patients
Patients at least 18 years of age and on long-term anticoagulation with dabigatran for any indication were eligible for the study. In addition, they had to be scheduled for elective surgery or an invasive procedure that required interruption of dabigatran treatment. Exclusion criteria were 1) any condition precluding collection of follow-up information, 2) inability to obtain Foundation of Canada. The manufacturer of dabigatran, Boehringer Ingelheim, ha ha ad d d no no no nvolvement in the main study described here although the company funded a substudy on the abo ora ra rato to tory ry ry a a ass ss s essm sm sment of the residual anticoagul lat at ati i io o on effect of dabigatra ra an n n on the day of surgery.
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The e e st st stud d udy wa a was s s ma ma mana na nage ge ged d d by b by t t the he he M M McM cM cMas as aste te ter r r Tr Tr Tran an ansf sf sfus s usio io ion n n Re Re Rese se sear ar arch ch ch P P Pro ro rogr gr gram am am. An An An informed consent, and 3) previous participation in this study for the same procedure. Half way through the study we introduced an exclusion criterion for patients planned for cardiac catheterization or electrophysiological study with ablation therapy to avoid dilution of the study population by too many low-risk procedures. Participating study sites were hospital-based Anticoagulation Clinics that routinely receive referrals for perioperative management of anticoagulation.
Study Procedures
The baseline visit occurred approximately one week before the planned procedure. At this visit data on patient characteristics, current antithrombotic treatment and type of planned surgery or procedure were collected. Blood was obtained for analysis of complete blood count and creatinine and the creatinine clearance was estimated using the Cockroft-Gault formula. 8 We gave oral and written instructions to the patient, with a copy to the referring physician and to the unit where the procedure would take place, regarding interruption and resumption of dabigatran. The timing of interruption was a refined version of the protocol amendment issued in 2008, half way through the phase III trials with dabigatran in atrial fibrillation and in treatment of venous thromboembolism and subsequently published. 9 Rather than time ranges we stipulated specific time points, still based on a) the creatinine clearance and the corresponding estimated half-life of dabigatran 10 and b) the surgery or procedure having standard or high risk of bleeding ( Table 1) . Procedures with increased risk of bleeding were listed in the protocol ( Table I in the online-only Data Supplement) but this classification was ultimately left to the discretion of the responsible physician or surgeon, since individual anatomical or pathological circumstances may alter the risk. There was no preoperative bridging with any parenteral anticoagulant, and it was left to the discretion of the local study site to interrupt or continue aspirin.
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On the day of surgery we asked the investigator, whenever feasible, to obtain a blood sample, preferably before the procedure. For patients with minor procedures performed early in the day sampling could alternatively be performed after the procedure, provided that heparin had not been given. Samples were analyzed to measure the activated partial thromboplastin time (aPTT) according to local routine. The results were not made available to the surgical team and
were not intended to influence the management.
The resumption of dabigatran was only after hemostasis had been secured, i.e. no ongoing bleeding. In addition, the protocol provided a list of surgical procedures with recommended resumption time and dose. For minor procedures resumption was in the evening of the procedure at a reduced dose of 75 mg, increasing to the regular dose (110 mg or 150 mg twice daily) the following morning. With increasing risk of bleeding the resumption time was delayed to 48 or 72 h after surgery and then starting with the regular dose ( Table II in the online-only Data Supplement). In case of indwelling catheter for neuraxial anesthesia, the first dose of dabigatran could only be given 4 h or more after removal of the catheter, as practiced in the phase III clinical trials with dabigatran in major orthopedic surgery.
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For patients with bowel paralysis after major abdominal surgery or a "no oral medications" order for any other reason, the resumption of dabigatran was delayed until intake of oral medications became possible. For such patients, bridging with low-molecular-weight heparin (LMWH) was recommended at doses decided by the local physician.
Patients were contacted after 1 week and 1 month (or visited if still in hospital) and medical records were reviewed for any outcomes. The follow-up ended at 1 month in accordance with recommendations of the International Society of Thrombosis and Haemostasis (ISTH).
Outcomes
The primary outcome was major bleeding, according to the ISTH definition for surgical studies (bleeding that is fatal or in a critical organ; extra-surgical site bleeding with a fall in hemoglobin of 20 g L -1 or requiring transfusion of 2 units of blood; surgical site bleeding that requires second intervention or causes hemarthrosis with delayed mobilization or wound healing, prolonged hospitalization or deep wound infection, or that is unexpected and prolonged and causes hemodynamic instability). 13 Adhering to the intention of this definition we also sought the assessment of the surgeon whether the bleeding was considered "unexpected and prolonged".
Secondary outcomes were arterial thromboembolic events, characterized as major (ischemic stroke or systemic embolism) or minor (transient ischemic attack). Minor bleeding, defined as any bleeding not fulfilling the criteria for major bleeding, was another secondary outcome. In addition, deaths were classified as caused by bleeding or thromboembolism or unrelated to any of those. A laboratory outcome was the aPTT on the day of procedure.
Statistical analyses
The sample size calculation took into account the best available data at the time of planning with respect to the risk for major bleeding in patients with interrupted warfarin therapy and perioperative bridging anticoagulation. This was obtained from a systematic review from 2005, in which the overall major bleed rate was 2.94% (95% confidence interval [CI], 2.28-3.74). 14 In this first prospective study we wanted to exclude a doubling of the risk of major bleeding compared to that historical control. With a one-sided alpha of 2.5%, a power of 80% and expected loss from follow-up of 10% our cohort study required a sample size of 283 patients.
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We analyzed data according to the intention-to-treat principle for the population that had the invasive procedure or surgery performed. Patients who were switched to another anticoagulant after surgery were still followed for 1 month.
Data are described with mean and standard deviation or, in case of skewed distribution, with median and interquartile range (IQR). Outcome rates are described as percent and 95% CI.
In addition, the event rate is compared with data from the above-mentioned systematic review 14 and with data from a more recent systematic review.
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Results
Between May 2012 and April 2014 we recruited 552 patients at 7 centers to the study. Eleven patients had their surgery cancelled. The remaining 541 patients had an invasive procedure or surgery and are included in the analysis (Fig. 1) . Their characteristics are shown in Table 2 .
Nine patients (1.7%) were lost to the 1-month follow-up.
The types of invasive procedures and surgeries performed are summarized in Table 3 .
Sixty percent of the procedures were considered by the investigators as of standard bleeding risk and 40% as high bleeding risk. The timing of last dose before and first dose after the procedures, both as planned and actual are shown in Table 4 . For 89% of the cases dabigatran was stopped according to protocol, i.e. 24 h (in 46%), 48 h (in 37%) and 96 h (in 6%) before surgery. For 5%
it was stopped a median of 2 days (IQR 1-3) earlier than planned, and for 4% a median of 1 day (IQR 1-1) later than planned (missing data on timing in 2%). Dabigatran was resumed a median of 1 day (IQR 0-2) after the procedure. For 77% of the cases dabigatran was resumed at the time (Fig g g. 1 1) . ) T Th h heir r r c c cha har r rac ct cter er e i i ist t tics cs cs a a are e sho ho how w wn in n n T T Tab ble e e 2.
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Ni Ni Nine ne ne p p pat at atie ie ient nt nts s s (1 (1 (1 7 7 .7%) %) %) wer er ere e e lo lo lost st st t t to o o th th the e e 1 1 1-mo mo mont nt nth h h fo fo foll ll llow o ow-up p p. provided by the protocol, for 3% it was resumed a median of 2 days (IQR 1-3) earlier than planned, and for 14% a median of 1 day (IQR 1-3) later than planned (missing data on timing in 5%). In 219 cases (40%) dabigatran was resumed with the first dose, which was 75 mg, in the evening of the day of procedure.
Preoperative bridging with a parenteral anticoagulant was not used at all, but 9 patients (1.7%) received postoperative heparin or LMWH, mainly after bowel resection or major vascular surgery.
There were 10 patients (1.8%; 95% CI, 0.7-3.0) with one major bleeding event each and 28 patients (5.2%; 95% CI, 3.3-7.0) with 35 minor bleeding events during the 30-day follow-up.
Nine of the patients with major bleeding events were males, the mean age of the 10 patients was 78 years, 9 had no risk factors for bleeding at inclusion but 8 had a procedure considered as high risk for bleeding (Table III in the online-only Data Supplement). For 21 of the patients with minor bleeds it was related to the surgical site, either as overt bleeding (15) or wound hematoma (6) . Eight of the overt bleeds were after urologic procedures. The extra-surgical site minor bleeds were hematochezia (2), hematuria (2), hemoptysis (2) and epistaxis (1).
Eight patients had neuraxial anesthesia for their surgery and another 5 had epidural injections as the qualifying procedure, all of which were uncomplicated.
There was only one thromboembolic event (0.2%; 95% CI, 0-0.5), a transient ischemic attack. Four patients (0.7%; 95% CI, 0-1.5) died of causes unrelated to bleeding or thrombosis, and 12 serious adverse events were reported.
A result for aPTT on the day of the procedure was obtained in 214 cases (40%) and the median was 32 s (IQR 29-36) ( Fig. 1 in the online-only Data Supplement). Twenty patients had aPTT above 40 s but they did not experience any bleeding. Of the 10 patients with major
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Discussion
This is the first study on perioperative management of dabigatran using a specified protocol for both the interruption and the resumption of the drug. We have shown that a protocol based on pharmacokinetic principles and the estimated bleeding risk is feasible, safe and does not require bridging with heparin. An interval of 24-96 h between the last dose of dabigatran and surgery or invasive procedure is sufficient for the vast majority of patients. Resumption of dabigatran occurred after 0-2 days in 73% of cases.
The incidence of major bleeding of 1.8% with a 95% CI of 0.7-3.0 in this population indicates that our protocol is unlikely to be associated with a doubling of the rate of major bleeding versus the patients with VKA interrupted for surgery (rate 2.94%), according to data from the systematic review we initially planned to compare with (odds ratio [OR] 0.62; 95% CI, 0.30-1.19). 14 During the period of our study a new systematic review on perioperative management of vitamin K antagonists, in which most patients received bridging with therapeutic dose LMWH, was published and our results also compare favorably with the rate of 4.3% in that review (OR 0.43; 95% CI, 0.21-0.78). 1 In a substudy of a randomized trial with dabigatran versus warfarin in atrial fibrillation, 5 the 30-day incidence of major bleeding among 2785 patients treated with dabigatran 110 or 150 mg twice daily and having elective surgery was 2.8% and 3.8%, respectively. 6 In a further analysis of this population, Douketis .0 in n n t t thi hi his s po po popu pu pula la lati i ion on on n n ndi di d ca ca cates that at at our r ur p p prot to oc co c l is s s un un nlike e ely ly ly t t to be b a a ass s sociat ted wi w with h a do do oub ub ubli l ng ng n o o of f the e e ra ra rate o o of f m m maj jo j r r r bl bl blee ee eedi di ding ng ng ver er ersu s sus s s th th the e e pa pa pati ti tien en ents ts ts wit it ith h h VK VK VKA A A in in inte te terr rr rrup p upte te ted d d f f for or or s s sur r urge ge gery r ry ( ( (ra ra rate te te 2 2 2 9 9 .94% 4% 4%) ) ), a a acc cc ccor or ordi di ding ng ng t t to o o da da data ta ta d d d incidence of major bleeding was significantly higher among the dabigatran-treated patients with than without perioperative bridging (6.5% vs. 1.8%). 15 In a registry from Dresden, reporting on 863 procedures in patients treated with different NOACs, the 30-day incidence of major bleeding was 1.2%, but 90% of the procedures were "minimal" or "minor". 16 Our study provides evidence that during the short interruption of dabigatran with our protocol there is no need for bridging with heparin unless dabigatran cannot be administered (e.g. ileus, naso-gastric feeding since dabigatran capsules must not be crushed) or there is a specific indication for heparin (e.g. vascular surgery). With a single event of transient ischemic attack (0.2%) and no major arterial thromboembolic events in 541 cases, there is no further efficacy to be gained with routine perioperative bridging. Similarly, in the analysis by Douketis et al the risk of thromboembolic events in non-bridged dabigatran-treated patients was 0.6%. 15 The guidelines from the American Society of Regional Anesthesia recommend stopping dabigatran 5 days before surgery with neuraxial block. 17 This is not based on clinical evidence but based on concern for the potential risk of epidural hematoma after neuraxial anesthesia. In our population we had 13 cases with surgery performed under neuraxial anesthesia or with epidural or spinal injection as the main procedure and no bleeding complications related to this; the 95% confidence interval for the risk is 0-25%. With a reported incidence of hemorrhagic complications resulting in neurologic deficit of 1 in 150,000 epidurals and 1 in 220,000 spinal anesthetics it will not be feasible to perform a study that can exclude increased risk of such events with perioperative management of any NOAC. 17 Major bleeding in this study population was managed with conservative measures, including transfusion of red cells for 6 of the 10 cases. For patients with major bleeding in association with emergency surgery or when dabigatran mistakenly was stopped late, more be gained with routine perioperative bridging. Similarly, in the analysis by Douket et etis is is e e et t t al al al t t the he he r r risk of thromboembolic events in non-bridged dabigatran-treated patients was 0.6%. d bu u ut t t b ba based on n n c c con n nce e ern f f fo or o the e e p pot ot o en n nti ti tia al r r ris s sk o o of e e epi p d dur r ral he he hema a ato o oma ma ma a a aft fter e e n n ne eura a axi xi xial a a ane ne nes st s he esi i ia. In n n ou o our r r po po popu p pula la lati ti tion on on we e e ha ha had d d 13 13 13 c c cas as ases es es wit it ith h h su s surg rg rger er ery pe pe perf rf rfor or orme me med d d un n unde de der r r ne ne neur r urax a axia ia ial l l an an anes es esth th thes es esia ia ia o o or r r wi i with th th active management may be required, including hemodialysis 7 or possibly infusion of 4-factor-or activated prothrombin complex concentrate 18, 19 . A specific antidote against dabigatran is currently evaluated in a clinical trial (ClinicalTrials.gov NCT02104947) and might be available in the near future.
The adherence, defined as following the protocol to the day, to our recommendation for timing of resumption of dabigatran (77%) was lower than the adherence to the stopping time (89%). This is not surprising, since it is in many cases difficult to predict the postoperative course. Assessment of the patient before resumption of any form of therapeutic anticoagulation is therefore warranted after all major procedures.
A limitation of our study is that it did not have a randomized control design. However, we wanted to evaluate a protocol based on our best knowledge of the pharmacokinetics of dabigatran in patients with normal or different degrees of impairment of renal function and on the clinician's assessment of the risk of bleeding combined with the guidance document from the protocol. We felt that a comparison with any other alternative perioperative dabigatran regimen that likely would be inferior was not justified. Another limitation is that the first postoperative dose of 75 mg, administered to 40% of our cases, is not widely available except in the United States (approved for atrial fibrillation) or at hospitals that use dabigatran for prophylaxis against thrombosis after hip-or knee replacement. We have therefore initiated another study, in which dabigatran is started at the earliest on the first day after surgery and at the regular maintenance dose (ClinicalTrials.gov NCT02228798).
In conclusion, our perioperative dabigatran protocol with timing for stopping and resuming anticoagulation based on renal function and procedure-related risk of bleeding appears safe and effective. The protocol is feasible with 89% adherence to the stopping recommendation A limitation of our study is that it did not have a randomized control desig g gn. n. n. H H How ow owev ev ever er er, d
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Funding Sources: The study was funded by a grant from Heart and Stroke Foundation of Canada. CL CR = calculated creatinine clearance a Data from renal impairment study in healthy volunteers, 10 geometric mean (range). b Types of surgery associated with a high risk of bleeding (or in major surgery where complete hemostasis may be required) include but is not limited to cardiac surgery, neurosurgery, abdominal surgery or those involving a major organ. Other procedures such as spinal anesthesia may also require complete hemostatic function. Other important determinants of bleeding risk include advancing age, co-morbidities (e.g. major cardiac, respiratory or liver disease) and concomitant use of antiplatelet therapy. See Appendix 1 for details. c Dabigatran etexilate is contraindicated for use in these patients, but if a patient was found to have CL CR <30 mL/min at the baseline visit we did not exclude the patient from the study.
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